Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Ulrich Costabel, Carlo Albera, Marilyn K. Glassberg, Lisa H. Lancaster, Wim A. Wuyts, Ute Petzinger, Frank Gilberg, Klaus-Uwe Kirchgaessler, Paul W. Noble

ABSTRACT

Data from controlled clinical studies in patients with more advanced idiopathic pulmonary fibrosis (IPF) could inform clinical practice, but they are limited, since this sub-population is usually excluded from clinical trials. These exploratory post-hoc analyses of the open-label, long-term extension study RECAP (NCT00662038) aimed to assess the efficacy and safety of pirfenidone in patients with more advanced IPF. Patients were categorised according to the extent of lung function impairment at baseline: more advanced (percent predicted FVC <50% and/or DLco <35%) and less advanced (percent predicted FVC ≥50% and DLco ≥35%).Overall, 596 patients with baseline FVC and/or DLco values available were included in the analyses; 187 patients had more advanced disease, and 409 patients had less advanced disease. Mean percent predicted FVC declined throughout 180 weeks of treatment in both more and less advanced disease subgroups. Both subgroups exhibited a similar pattern of adverse events; however, adverse events related to IPF progression were experienced by a higher proportion of patients with more advanced versus less advanced disease. Discontinuation rates due to any reason, adverse events related to IPF progression, or deaths were each higher in the more advanced versus the less advanced disease subgroup.These analyses found that longer-term pirfenidone treatment resulted in a similar rate of lung function decline and safety profile in patients with more advanced versus less advanced IPF, and the data suggest that pirfenidone is efficacious, well tolerated, and a feasible treatment option in patients with more advanced IPF. More... »

PAGES

55

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12931-019-1021-2

DOI

http://dx.doi.org/10.1186/s12931-019-1021-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112739118

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30866942


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Ruhrlandklinik, University Hospital, University of Duisburg-Essen, T\u00fcschener Weg, 45239, Essen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Costabel", 
        "givenName": "Ulrich", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Turin", 
          "id": "https://www.grid.ac/institutes/grid.7605.4", 
          "name": [
            "Department of Clinical and Biological Sciences, Interstitial and Rare Lung Disease Unit, University of Turin, Regione Gonzole 10, 10043, Orbassano, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Albera", 
        "givenName": "Carlo", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Miami Health System", 
          "id": "https://www.grid.ac/institutes/grid.418456.a", 
          "name": [
            "Departments of Medicine, Surgery, and Pediatrics, University of Miami Health System, 1321 14th Street, Suite 510, 33125, Miami, FL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Glassberg", 
        "givenName": "Marilyn K.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Vanderbilt University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.412807.8", 
          "name": [
            "Department of Medicine, Vanderbilt University Medical Center, 1211 Medical Center Drive, 37232, Nashville, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lancaster", 
        "givenName": "Lisa H.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universitaire Ziekenhuizen Leuven", 
          "id": "https://www.grid.ac/institutes/grid.410569.f", 
          "name": [
            "Department of Respiratory Medicine, Unit for Interstitial Lung Diseases, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wuyts", 
        "givenName": "Wim A.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Accovion GmbH, Helfmann-Park 10, 65760, Eschborn, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Petzinger", 
        "givenName": "Ute", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.417570.0", 
          "name": [
            "F. Hoffmann-La Roche, Ltd., Konzem-Hauptsitz, Grenzacherstrasse 124, CH-4070, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gilberg", 
        "givenName": "Frank", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.417570.0", 
          "name": [
            "F. Hoffmann-La Roche, Ltd., Konzem-Hauptsitz, Grenzacherstrasse 124, CH-4070, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kirchgaessler", 
        "givenName": "Klaus-Uwe", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cedars-Sinai Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.50956.3f", 
          "name": [
            "Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Blvd, 90048, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Noble", 
        "givenName": "Paul W.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0140-6736(11)60405-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009123817"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1164/rccm.2009-040gl", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009587829"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1402582", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013090473"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1164/rccm.201006-0894ci", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016956304"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1378/chest.10-2572", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033922879"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1402584", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048572484"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00408-016-9912-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050449289", 
          "https://doi.org/10.1007/s00408-016-9912-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00408-016-9912-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050449289", 
          "https://doi.org/10.1007/s00408-016-9912-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/resp.12989", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083687170"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000479976", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091608456"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "Data from controlled clinical studies in patients with more advanced idiopathic pulmonary fibrosis (IPF) could inform clinical practice, but they are limited, since this sub-population is usually excluded from clinical trials. These exploratory post-hoc analyses of the open-label, long-term extension study RECAP (NCT00662038) aimed to assess the efficacy and safety of pirfenidone in patients with more advanced IPF. Patients were categorised according to the extent of lung function impairment at baseline: more advanced (percent predicted FVC <50% and/or DLco <35%) and less advanced (percent predicted FVC \u226550% and DLco \u226535%).Overall, 596 patients with baseline FVC and/or DLco values available were included in the analyses; 187 patients had more advanced disease, and 409 patients had less advanced disease. Mean percent predicted FVC declined throughout 180\u2009weeks of treatment in both more and less advanced disease subgroups. Both subgroups exhibited a similar pattern of adverse events; however, adverse events related to IPF progression were experienced by a higher proportion of patients with more advanced versus less advanced disease. Discontinuation rates due to any reason, adverse events related to IPF progression, or deaths were each higher in the more advanced versus the less advanced disease subgroup.These analyses found that longer-term pirfenidone treatment resulted in a similar rate of lung function decline and safety profile in patients with more advanced versus less advanced IPF, and the data suggest that pirfenidone is efficacious, well tolerated, and a feasible treatment option in patients with more advanced IPF.", 
    "genre": "non_research_article", 
    "id": "sg:pub.10.1186/s12931-019-1021-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1028525", 
        "issn": [
          "1465-9921", 
          "1465-993X"
        ], 
        "name": "Respiratory Research", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "name": "Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis", 
    "pagination": "55", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "63a48542f9341afff0747f784442db4727d98670737b2b296141ae1b4f48be0c"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30866942"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101090633"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12931-019-1021-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112739118"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12931-019-1021-2", 
      "https://app.dimensions.ai/details/publication/pub.1112739118"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:19", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000368_0000000368/records_78950_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12931-019-1021-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12931-019-1021-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12931-019-1021-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12931-019-1021-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12931-019-1021-2'


 

This table displays all metadata directly associated to this object as RDF triples.

163 TRIPLES      21 PREDICATES      38 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12931-019-1021-2 schema:about anzsrc-for:11
2 anzsrc-for:1102
3 schema:author Nec8997723dd84d22b33822a7c185e33c
4 schema:citation sg:pub.10.1007/s00408-016-9912-1
5 https://doi.org/10.1016/s0140-6736(11)60405-4
6 https://doi.org/10.1056/nejmoa1402582
7 https://doi.org/10.1056/nejmoa1402584
8 https://doi.org/10.1111/resp.12989
9 https://doi.org/10.1159/000479976
10 https://doi.org/10.1164/rccm.2009-040gl
11 https://doi.org/10.1164/rccm.201006-0894ci
12 https://doi.org/10.1378/chest.10-2572
13 schema:datePublished 2019-12
14 schema:datePublishedReg 2019-12-01
15 schema:description Data from controlled clinical studies in patients with more advanced idiopathic pulmonary fibrosis (IPF) could inform clinical practice, but they are limited, since this sub-population is usually excluded from clinical trials. These exploratory post-hoc analyses of the open-label, long-term extension study RECAP (NCT00662038) aimed to assess the efficacy and safety of pirfenidone in patients with more advanced IPF. Patients were categorised according to the extent of lung function impairment at baseline: more advanced (percent predicted FVC <50% and/or DLco <35%) and less advanced (percent predicted FVC ≥50% and DLco ≥35%).Overall, 596 patients with baseline FVC and/or DLco values available were included in the analyses; 187 patients had more advanced disease, and 409 patients had less advanced disease. Mean percent predicted FVC declined throughout 180 weeks of treatment in both more and less advanced disease subgroups. Both subgroups exhibited a similar pattern of adverse events; however, adverse events related to IPF progression were experienced by a higher proportion of patients with more advanced versus less advanced disease. Discontinuation rates due to any reason, adverse events related to IPF progression, or deaths were each higher in the more advanced versus the less advanced disease subgroup.These analyses found that longer-term pirfenidone treatment resulted in a similar rate of lung function decline and safety profile in patients with more advanced versus less advanced IPF, and the data suggest that pirfenidone is efficacious, well tolerated, and a feasible treatment option in patients with more advanced IPF.
16 schema:genre non_research_article
17 schema:inLanguage en
18 schema:isAccessibleForFree true
19 schema:isPartOf N1dfd5b7d05c8462e95fd4509a3884aab
20 N943ca3d062a748e49a7c62fa68a49104
21 sg:journal.1028525
22 schema:name Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
23 schema:pagination 55
24 schema:productId N007a47f639004f1a8d191954bbb447d2
25 N6569151c969549fe8f2b3cd251a1ae72
26 N6da1b9f1ea494096908dfb5b6bb445db
27 Ncfa8d109fab14f36bbaeeacde051a105
28 Ned457a7e2d064966854a6aa23610b3b5
29 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112739118
30 https://doi.org/10.1186/s12931-019-1021-2
31 schema:sdDatePublished 2019-04-11T13:19
32 schema:sdLicense https://scigraph.springernature.com/explorer/license/
33 schema:sdPublisher N5f18abe523d6416aaa979d1760ee6da0
34 schema:url https://link.springer.com/10.1186%2Fs12931-019-1021-2
35 sgo:license sg:explorer/license/
36 sgo:sdDataset articles
37 rdf:type schema:ScholarlyArticle
38 N007a47f639004f1a8d191954bbb447d2 schema:name nlm_unique_id
39 schema:value 101090633
40 rdf:type schema:PropertyValue
41 N06df6e312872422fb036f37db4e7835f rdf:first Na9bf3f939ab34a75b8a5988377658977
42 rdf:rest Nad43f6731f444d04aa8b423ad0bdb3e4
43 N0d5103b19bc348ca8d491c1793260c56 rdf:first Nbb2629cd4ff042d7b9e74bb2f6ff2314
44 rdf:rest N71fadd6d2f594197b59d6603ce0bd80e
45 N100dd6a273f443ad95e965452184f4bc schema:affiliation N97bd13715ae14b9c94fa1ab5dce6a21d
46 schema:familyName Costabel
47 schema:givenName Ulrich
48 rdf:type schema:Person
49 N10533c0d8f4b46ce9d010f598b16c2ee rdf:first N348327fbb40749e2b273ff0bd8973c43
50 rdf:rest N0d5103b19bc348ca8d491c1793260c56
51 N14576caa09464726af591cb325a338ad rdf:first N9b656f024ce147a6b7630dfc8676acaf
52 rdf:rest Nc35e7e1ae7834665814020b141ed571d
53 N1a9ed064dee3414caf87ef82e17022b6 schema:affiliation https://www.grid.ac/institutes/grid.417570.0
54 schema:familyName Gilberg
55 schema:givenName Frank
56 rdf:type schema:Person
57 N1dfd5b7d05c8462e95fd4509a3884aab schema:volumeNumber 20
58 rdf:type schema:PublicationVolume
59 N348327fbb40749e2b273ff0bd8973c43 schema:affiliation https://www.grid.ac/institutes/grid.7605.4
60 schema:familyName Albera
61 schema:givenName Carlo
62 rdf:type schema:Person
63 N5f18abe523d6416aaa979d1760ee6da0 schema:name Springer Nature - SN SciGraph project
64 rdf:type schema:Organization
65 N6569151c969549fe8f2b3cd251a1ae72 schema:name dimensions_id
66 schema:value pub.1112739118
67 rdf:type schema:PropertyValue
68 N6da1b9f1ea494096908dfb5b6bb445db schema:name pubmed_id
69 schema:value 30866942
70 rdf:type schema:PropertyValue
71 N71fadd6d2f594197b59d6603ce0bd80e rdf:first Nc0f9fd15aca54cd9bea3e979348c4590
72 rdf:rest Nc1625e5a9cf2482f984513fd8be066be
73 N943ca3d062a748e49a7c62fa68a49104 schema:issueNumber 1
74 rdf:type schema:PublicationIssue
75 N97bd13715ae14b9c94fa1ab5dce6a21d schema:name Ruhrlandklinik, University Hospital, University of Duisburg-Essen, Tüschener Weg, 45239, Essen, Germany
76 rdf:type schema:Organization
77 N9b656f024ce147a6b7630dfc8676acaf schema:affiliation Nccdd385d92934e7b9126984a1225ed87
78 schema:familyName Petzinger
79 schema:givenName Ute
80 rdf:type schema:Person
81 Na9bf3f939ab34a75b8a5988377658977 schema:affiliation https://www.grid.ac/institutes/grid.417570.0
82 schema:familyName Kirchgaessler
83 schema:givenName Klaus-Uwe
84 rdf:type schema:Person
85 Naba0824cca76491f8ff15bcb37ae83d7 schema:affiliation https://www.grid.ac/institutes/grid.410569.f
86 schema:familyName Wuyts
87 schema:givenName Wim A.
88 rdf:type schema:Person
89 Nad43f6731f444d04aa8b423ad0bdb3e4 rdf:first Nd030f60a675144789b84d5e33958f0e5
90 rdf:rest rdf:nil
91 Nbb2629cd4ff042d7b9e74bb2f6ff2314 schema:affiliation https://www.grid.ac/institutes/grid.418456.a
92 schema:familyName Glassberg
93 schema:givenName Marilyn K.
94 rdf:type schema:Person
95 Nc0f9fd15aca54cd9bea3e979348c4590 schema:affiliation https://www.grid.ac/institutes/grid.412807.8
96 schema:familyName Lancaster
97 schema:givenName Lisa H.
98 rdf:type schema:Person
99 Nc1625e5a9cf2482f984513fd8be066be rdf:first Naba0824cca76491f8ff15bcb37ae83d7
100 rdf:rest N14576caa09464726af591cb325a338ad
101 Nc35e7e1ae7834665814020b141ed571d rdf:first N1a9ed064dee3414caf87ef82e17022b6
102 rdf:rest N06df6e312872422fb036f37db4e7835f
103 Nccdd385d92934e7b9126984a1225ed87 schema:name Accovion GmbH, Helfmann-Park 10, 65760, Eschborn, Germany
104 rdf:type schema:Organization
105 Ncfa8d109fab14f36bbaeeacde051a105 schema:name doi
106 schema:value 10.1186/s12931-019-1021-2
107 rdf:type schema:PropertyValue
108 Nd030f60a675144789b84d5e33958f0e5 schema:affiliation https://www.grid.ac/institutes/grid.50956.3f
109 schema:familyName Noble
110 schema:givenName Paul W.
111 rdf:type schema:Person
112 Nec8997723dd84d22b33822a7c185e33c rdf:first N100dd6a273f443ad95e965452184f4bc
113 rdf:rest N10533c0d8f4b46ce9d010f598b16c2ee
114 Ned457a7e2d064966854a6aa23610b3b5 schema:name readcube_id
115 schema:value 63a48542f9341afff0747f784442db4727d98670737b2b296141ae1b4f48be0c
116 rdf:type schema:PropertyValue
117 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
118 schema:name Medical and Health Sciences
119 rdf:type schema:DefinedTerm
120 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
121 schema:name Cardiorespiratory Medicine and Haematology
122 rdf:type schema:DefinedTerm
123 sg:journal.1028525 schema:issn 1465-9921
124 1465-993X
125 schema:name Respiratory Research
126 rdf:type schema:Periodical
127 sg:pub.10.1007/s00408-016-9912-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050449289
128 https://doi.org/10.1007/s00408-016-9912-1
129 rdf:type schema:CreativeWork
130 https://doi.org/10.1016/s0140-6736(11)60405-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009123817
131 rdf:type schema:CreativeWork
132 https://doi.org/10.1056/nejmoa1402582 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013090473
133 rdf:type schema:CreativeWork
134 https://doi.org/10.1056/nejmoa1402584 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048572484
135 rdf:type schema:CreativeWork
136 https://doi.org/10.1111/resp.12989 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083687170
137 rdf:type schema:CreativeWork
138 https://doi.org/10.1159/000479976 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091608456
139 rdf:type schema:CreativeWork
140 https://doi.org/10.1164/rccm.2009-040gl schema:sameAs https://app.dimensions.ai/details/publication/pub.1009587829
141 rdf:type schema:CreativeWork
142 https://doi.org/10.1164/rccm.201006-0894ci schema:sameAs https://app.dimensions.ai/details/publication/pub.1016956304
143 rdf:type schema:CreativeWork
144 https://doi.org/10.1378/chest.10-2572 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033922879
145 rdf:type schema:CreativeWork
146 https://www.grid.ac/institutes/grid.410569.f schema:alternateName Universitaire Ziekenhuizen Leuven
147 schema:name Department of Respiratory Medicine, Unit for Interstitial Lung Diseases, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium
148 rdf:type schema:Organization
149 https://www.grid.ac/institutes/grid.412807.8 schema:alternateName Vanderbilt University Medical Center
150 schema:name Department of Medicine, Vanderbilt University Medical Center, 1211 Medical Center Drive, 37232, Nashville, TN, USA
151 rdf:type schema:Organization
152 https://www.grid.ac/institutes/grid.417570.0 schema:alternateName Roche (Switzerland)
153 schema:name F. Hoffmann-La Roche, Ltd., Konzem-Hauptsitz, Grenzacherstrasse 124, CH-4070, Basel, Switzerland
154 rdf:type schema:Organization
155 https://www.grid.ac/institutes/grid.418456.a schema:alternateName University of Miami Health System
156 schema:name Departments of Medicine, Surgery, and Pediatrics, University of Miami Health System, 1321 14th Street, Suite 510, 33125, Miami, FL, USA
157 rdf:type schema:Organization
158 https://www.grid.ac/institutes/grid.50956.3f schema:alternateName Cedars-Sinai Medical Center
159 schema:name Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Blvd, 90048, Los Angeles, CA, USA
160 rdf:type schema:Organization
161 https://www.grid.ac/institutes/grid.7605.4 schema:alternateName University of Turin
162 schema:name Department of Clinical and Biological Sciences, Interstitial and Rare Lung Disease Unit, University of Turin, Regione Gonzole 10, 10043, Orbassano, Italy
163 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...